查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2029974

全球眼高壓市場：按治療類型、藥物類型、分銷管道、給藥途徑和地區分類－市場規模、行業動態、機會分析和預測（2026-2035 年）

Global Ocular Hypertension Market: By Treatment Type, Drug Type, Distribution Channel, Route of Administration, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球眼高壓市場呈現穩定持續成長態勢，反映出全球眼科疾病負擔日益加重以及對有效眼壓管理的需求不斷成長。 2025年，該市場規模約為42.8億美元，預計到2035年將達到約94.3億美元。這一成長意味著2026年至2035年預測期內的複合年成長率約為8.22%，顯示在臨床和技術因素的雙重驅動下，該市場將實現強勁的長期擴張。

推動這一上升趨勢的主要因素之一是全球人口老化。隨著已開發經濟體和新興經濟體老年人口比例的持續成長，眼壓升高等眼科疾病的發生率也上升。由於老齡化是眼壓升高的既定風險因素，定期篩檢和長期管理變得日益重要，這反過來又推動了對診斷工具和治療性介入的需求。

顯著的市場趨勢

多家大型製藥企業在塑造眼高壓治療趨勢方面發揮核心作用，除了前列腺素和BETA阻斷劑現有藥物外，它們還致力於開發新一代治療方法。這些公司不斷加大研發投入，旨在改善眼壓控制，提高病患遵守用藥，並拓展傳統治療方法以外的治療選擇。

Nicox SA是該領域知名的公司之一，尤其以其在氧化氮供體療法方面的創新工作而聞名。其旗艦候選產品NCX 470是一種基於Bimatoprost的滴眼液，它結合了前列腺​​素的作用和一氧化氮的釋放，有望產生更強的降低眼內壓的效果。 Alcon憑藉其涵蓋藥品和手術解決方案的廣泛產品組合，在全球眼科護理市場也佔有重要地位。

艾伯維憑藉其在眼科領域的卓越成就，與艾爾建公司合作，在眼壓和眼表疾病的治療領域繼續發揮主導作用。美達製藥株式會社也是重要的合作夥伴，尤其致力於新型前列腺素衍生物的研發。該公司正在開發諸如塞培前列素等先進分子，旨在提高療效和耐受性，以優於傳統治療方法。

關鍵成長要素

受全球人口和健康趨勢的強勁推動，眼高壓治療市場總潛在規模（TAM）正在穩步擴大。其中一個最重要的因素是世界人口老化，因為眼科疾病風險會隨著老齡化的成長而顯著增加。隨著已開發經濟體和新興經濟體預期壽命的延長，越來越多的人口進入高風險年齡層，易受眼壓升高影響的人口基數也持續增加。

新機會的趨勢

眼高壓市場的商業性可行性與能否早期準確檢測疾病密切相關。早期診斷不僅能改善臨床療效，還能在疾病發展到更嚴重階段之前識別出大量患者，從而顯著擴大目標患者群體。到2025年，隨著人工智慧（AI）和機器學習（ML）演算法融入診斷流程，這個過程將發生根本性變革。

最佳化障礙

眼高壓藥物市場監管環境複雜，製藥公司需要雄厚的財力和長期的投入。美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構對眼科藥物的核准標準極為嚴格。這些機構高度重視可靠的臨床證據，尤其要求設計非劣效性治療方法與現有治療方法相當或更優。除了療效之外，眼表安全性、耐受性和患者的長期預後也備受關注，這體現了眼科治療的特殊性。

目錄

第1章執行摘要：全球眼高壓市場

第2章：報告概述

  • 研究框架
    • 研究目標
    • 市場的定義
    • 市場區隔
  • 調查方法
    • 市場規模估算
    • 定性研究
      • 一手和二手資訊
    • 量化研究
      • 一手和二手資訊
    • 主要調查受訪者組成：依國家分類
    • 數據三角測量
    • 本研究的前提

第3章：全球眼高壓市場概覽

  • 產業價值鏈分析
  • 產業展望
    • 擴大眼科藥物組合，以支持早期眼科疾病管理。
  • PESTLE分析
  • 波特五力分析
  • 市場成長及前景
    • 2020-2035年市場收入估算與預測
  • 市場吸引力分析
    • 依藥物類型
  • 可執行的見解（分析師建議）

第4章：競爭對手儀錶板

  • 市場集中度
  • 企業市場占有率分析，2025 年
  • 競爭對手分析與基準測試

第5章：全球眼高壓市場分析

  • 市場動態和趨勢
    • 成長要素
      • 青光眼盛行率不斷上升和人口老化
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測，2020-2035年
    • 依藥物類型
      • 關鍵見解
        • 前列腺素類似物
          • 拉坦前列素
          • Bimatoprost
        • BETA受體阻斷劑
          • 蒂莫羅爾
          • 倍他索
        • α受體促效劑
          • 溴莫尼定
        • 碳酸酐酶抑制劑
          • 多佐胺
          • 布林佐胺
        • 組合藥物
          • 固定劑量組合藥物
    • 治療類型
      • 關鍵見解
        • 藥物治療
          • 外用藥物
          • 口服藥物
        • 手術治療
          • 雷射手術
          • 切除術
          • 嵌入式裝置
        • 其他
          • 生活方式改善
    • 透過行政途徑
      • 關鍵見解
        • 外用
          • 眼藥水
        • 口服
          • 口服藥物
        • 其他
          • 注射藥物
    • 透過分銷管道
      • 關鍵見解
        • 醫院和診所
          • 眼科診所
          • 醫院
        • 零售藥房
          • 連鎖藥局
          • 獨立藥房
        • 網路藥房
    • 按地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 韓國
          • 澳洲和紐西蘭
          • ASEAN
            • 印尼
            • 馬來西亞
            • 泰國
            • 新加坡
            • 其他東南亞國協
          • 其他亞太國家
        • 中東和非洲
          • UAE
          • 沙烏地阿拉伯
          • 南非
          • 其他中東和非洲國家
        • 南美洲
          • 阿根廷
          • 巴西
          • 其他南美國家

第6章：北美眼高壓市場分析

第7章：歐洲眼高壓市場分析

第8章：亞太地區眼高壓市場分析

第9章：中東和非洲眼高壓市場分析

第10章：南美洲眼高壓市場分析

第11章：公司簡介

  • AbbVie
  • Bausch+Lomb
  • Alcon
  • Qlaris Bio
  • Santen Pharmaceuticals
  • Noveome Therapeutics
  • Nicox
  • Kowa Pharmaceuticals
  • Other Prominent Players

第12章附錄

簡介目錄
Product Code: AA04261763

The global ocular hypertension market is demonstrating consistent and sustained growth, reflecting the increasing global burden of eye-related disorders and the expanding need for effective intraocular pressure management. In 2025, the market was valued at approximately USD 4.28 billion, and it is projected to reach around USD 9.43 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of about 8.22% during the forecast period from 2026 to 2035, indicating strong long-term expansion driven by both clinical and technological factors.

One of the primary forces behind this upward trajectory is the global aging population. As the proportion of elderly individuals continues to rise across both developed and emerging economies, the incidence of ocular conditions such as ocular hypertension also increases. Aging is a well-established risk factor for elevated intraocular pressure, making regular screening and long-term management more critical, which in turn drives demand for diagnostic tools and therapeutic interventions.

Noteworthy Market Developments

Several major pharmaceutical companies play a central role in shaping the ocular hypertension treatment landscape, with a strong focus on both established drug classes such as prostaglandins and beta-blockers, as well as the development of next-generation therapies. These companies are continuously investing in research and innovation to improve intraocular pressure management, enhance patient compliance, and expand therapeutic options beyond conventional treatments.

Nicox SA is one of the notable players in this space, particularly recognized for its work on innovative nitric oxide-donating therapies. The company's lead candidate, NCX 470, is a bimatoprost-based eye drop designed to combine prostaglandin activity with nitric oxide donation, potentially offering enhanced intraocular pressure reduction. Alcon also holds a significant position in the global eye care market, with a broad portfolio that spans both pharmaceutical and surgical solutions.

AbbVie Inc., through its ophthalmic legacy associated with Allergan, remains a leading force in ocular pressure and surface disease management. Santen Pharmaceutical Co., Ltd. is another key contributor, particularly active in the development of novel prostaglandin derivatives. The company is working on advanced molecules such as sepetaprost, which aim to improve efficacy and tolerability compared to traditional therapies.

Core Growth Drivers

The Total Addressable Market (TAM) for ocular hypertension is expanding steadily, driven by powerful global demographic and health trends. One of the most significant contributors is the aging population worldwide, as the risk of ocular conditions increases substantially with age. As life expectancy rises across both developed and emerging economies, a larger proportion of the global population is entering higher-risk age brackets, creating a continuously growing base of individuals susceptible to elevated intraocular pressure.

Emerging Opportunity Trends

The commercial viability of the ocular hypertension market is closely tied to the ability to detect the condition early and accurately. Early diagnosis not only improves clinical outcomes but also significantly expands the addressable patient population, as more individuals are identified before the disease progresses to more severe stages. In 2025, this process has been fundamentally transformed by the integration of artificial intelligence (AI) and machine learning (ML) algorithms into diagnostic workflows.

Barriers to Optimization

Navigating the regulatory landscape in the ocular hypertension market demands substantial financial strength and long-term commitment from pharmaceutical companies. Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) maintain highly stringent approval standards for ophthalmic drugs. These agencies place strong emphasis on robust clinical evidence, particularly requiring non-inferiority trial designs to demonstrate that new therapies are at least as effective as existing treatments. In addition to efficacy, there is also significant focus on ocular surface safety, tolerability, and long-term patient outcomes, reflecting the sensitive nature of eye-related treatments.

Detailed Market Segmentation

By drug type, the prostaglandin analogs segment held the leading position in the ocular hypertension market in 2025, accounting for approximately 42.50% of the total share. This dominance reflects their strong clinical efficacy, widespread adoption in treatment guidelines, and established role as the preferred first-line therapy for reducing intraocular pressure in patients with ocular hypertension.

By treatment type, the medical treatment segment dominated the ocular hypertension market in 2025, accounting for approximately 71.23% of the total share. This strong position reflects its established role as the primary and most widely adopted approach for managing elevated intraocular pressure. Medical treatments are deeply embedded in global ophthalmic care practices and remain the standard first-line option recommended by clinical guidelines before any consideration of surgical intervention.

By distribution channel, the retail pharmacies segment held the dominant position in the ocular hypertension market in 2025, accounting for nearly 43% of the total share. This leadership reflects the strong role retail pharmacies play as the most accessible and widely used point of contact for patients seeking prescription eye medications. Their extensive geographic reach, including presence in both urban centers and smaller communities, ensures consistent availability of ocular hypertension treatments and supports long-term medication adherence among patients.

By route of administration, the topical segment held the dominant position in the ocular hypertension market, accounting for approximately 78% of the total share. This overwhelming preference for topical therapies reflects both clinical practicality and patient-centered advantages, making them the most widely used treatment approach for managing elevated intraocular pressure. The primary reason for this dominance lies in the non-invasive nature of topical formulations, which are typically administered in the form of eye drops.

Segment Breakdown

By Drug Type

  • Prostaglandin Analogs
  • Latanoprost
  • Bimatoprost
  • Beta-Blockers
  • Timolol
  • Betaxolol
  • Alpha Agonists
  • Brimonidine
  • Carbonic Anhydrase Inhibitors
  • Dorzolamide
  • Brinzolamide
  • Combination Drugs
  • Fixed-dose combinations

By Treatment Type

  • Medical Treatment
  • Topical Drugs
  • Oral Drugs
  • Surgical Treatment
  • Laser Surgery
  • Trabeculectomy
  • Implantable Devices
  • Others
  • Lifestyle Modifications

By Route of Administration

  • Topical
  • Eye Drops
  • Oral
  • Oral Medications
  • Others
  • Injectable

By Distribution Channel

  • Hospitals & Clinics
  • Ophthalmology Clinics
  • Hospitals
  • Retail Pharmacies
  • Chain Pharmacies
  • Independent Pharmacies
  • Online Pharmacies

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America held the leading position in the ocular hypertension market in 2025, accounting for approximately 43.10% of the global share. This dominance is not coincidental but instead reflects deeply rooted structural strengths within the region's healthcare system and broader medical ecosystem. The region consistently outperforms others in ophthalmic care due to its advanced infrastructure, high treatment accessibility, and strong emphasis on early diagnosis and disease management.
  • A key factor behind this leadership is the exceptionally high level of healthcare expenditure across North America, particularly in the United States. Substantial financial investment in healthcare allows for widespread availability of advanced diagnostic tools, specialist care, and innovative treatment options. This high spending capacity supports continuous upgrades in medical technology and ensures that patients have access to cutting-edge therapies for conditions such as ocular hypertension and related eye disorders.

Leading Market Participants

  • AbbVie
  • Bausch + Lomb
  • Alcon
  • Qlaris Bio
  • Santen Pharmaceuticals
  • Noveome Therapeutics
  • Nicox
  • Kowa Pharmaceuticals
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Ocular Hypertension Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Country
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Global Ocular Hypertension Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Drug Discovery & Research
    • 3.1.2. Clinical Development
    • 3.1.3. Regulatory Approval
    • 3.1.4. Manufacturing & Production
    • 3.1.5. Distribution & Supply Chain
    • 3.1.6. Healthcare Providers / Prescribers
    • 3.1.7. End Users
    • 3.1.8. Post-Market Surveillance & Support
  • 3.2. Industry Outlook
    • 3.2.1. Expanding Ophthalmic Therapeutics Portfolio Supporting Early-Stage Eye Condition Management
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Drug Type
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Ocular Hypertension Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
      • 5.1.1.1. Increasing Prevalence of Glaucoma and Aging Population
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Drug Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Prostaglandin Analogs
          • 5.2.1.1.1.1. Latanoprost
          • 5.2.1.1.1.2. Bimatoprost
        • 5.2.1.1.2. Beta-Blockers
          • 5.2.1.1.2.1. Timolol
          • 5.2.1.1.2.2. Betaxolol
        • 5.2.1.1.3. Alpha Agonists
          • 5.2.1.1.3.1. Brimonidine
        • 5.2.1.1.4. Carbonic Anhydrase Inhibitors
          • 5.2.1.1.4.1. Dorzolamide
          • 5.2.1.1.4.2. Brinzolamide
        • 5.2.1.1.5. Combination Drugs
          • 5.2.1.1.5.1. Fixed-dose combinations
    • 5.2.2. By Treatment Type
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Medical Treatment
          • 5.2.2.1.1.1. Topical Drugs
          • 5.2.2.1.1.2. Oral Drugs
        • 5.2.2.1.2. Surgical Treatment
          • 5.2.2.1.2.1. Laser Surgery
          • 5.2.2.1.2.2. Trabeculectomy
          • 5.2.2.1.2.3. Implantable Devices
        • 5.2.2.1.3. Others
          • 5.2.2.1.3.1. Lifestyle Modifications
    • 5.2.3. By Route of Administration
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Topical
          • 5.2.3.1.1.1. Eye Drops
        • 5.2.3.1.2. Oral
          • 5.2.3.1.2.1. Oral Medications
        • 5.2.3.1.3. Others
          • 5.2.3.1.3.1. Injectable
    • 5.2.4. By Distribution Channel
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Hospitals & Clinics
          • 5.2.4.1.1.1. Ophthalmology Clinics
          • 5.2.4.1.1.2. Hospitals
        • 5.2.4.1.2. Retail Pharmacies
          • 5.2.4.1.2.1. Chain Pharmacies
          • 5.2.4.1.2.2. Independent Pharmacies
        • 5.2.4.1.3. Online Pharmacies
    • 5.2.5. By Region
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. North America
          • 5.2.5.1.1.1. The U.S.
          • 5.2.5.1.1.2. Canada
          • 5.2.5.1.1.3. Mexico
        • 5.2.5.1.2. Europe
          • 5.2.5.1.2.1. Western Europe
            • 5.2.5.1.2.1.1. The UK
            • 5.2.5.1.2.1.2. Germany
            • 5.2.5.1.2.1.3. France
            • 5.2.5.1.2.1.4. Italy
            • 5.2.5.1.2.1.5. Spain
            • 5.2.5.1.2.1.6. Rest of Western Europe
          • 5.2.5.1.2.2. Eastern Europe
            • 5.2.5.1.2.2.1. Poland
            • 5.2.5.1.2.2.2. Russia
            • 5.2.5.1.2.2.3. Rest of Eastern Europe
        • 5.2.5.1.3. Asia Pacific
          • 5.2.5.1.3.1. China
          • 5.2.5.1.3.2. India
          • 5.2.5.1.3.3. Japan
          • 5.2.5.1.3.4. South Korea
          • 5.2.5.1.3.5. Australia & New Zealand
          • 5.2.5.1.3.6. ASEAN
            • 5.2.5.1.3.6.1. Indonesia
            • 5.2.5.1.3.6.2. Malaysia
            • 5.2.5.1.3.6.3. Thailand
            • 5.2.5.1.3.6.4. Singapore
            • 5.2.5.1.3.6.5. Rest of ASEAN
          • 5.2.5.1.3.7. Rest of Asia Pacific
        • 5.2.5.1.4. Middle East & Africa
          • 5.2.5.1.4.1. UAE
          • 5.2.5.1.4.2. Saudi Arabia
          • 5.2.5.1.4.3. South Africa
          • 5.2.5.1.4.4. Rest of MEA
        • 5.2.5.1.5. South America
          • 5.2.5.1.5.1. Argentina
          • 5.2.5.1.5.2. Brazil
          • 5.2.5.1.5.3. Rest of South America

Chapter 6. North America Ocular Hypertension Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Drug Type
    • 6.2.2. By Treatment Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country

Chapter 7. Europe Ocular Hypertension Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Drug Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country

Chapter 8. Asia Pacific Ocular Hypertension Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Drug Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country

Chapter 9. Middle East & Africa Ocular Hypertension Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Drug Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country

Chapter 10. South America Ocular Hypertension Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Drug Type
    • 10.2.2. By Treatment Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

  • 11.1. AbbVie
  • 11.2. Bausch + Lomb
  • 11.3. Alcon
  • 11.4. Qlaris Bio
  • 11.5. Santen Pharmaceuticals
  • 11.6. Noveome Therapeutics
  • 11.7. Nicox
  • 11.8. Kowa Pharmaceuticals
  • 11.9. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators